Olmesartan Vir (Olmesartan Medoxomil)

Olmesartan Medoxomil, the active ingredient in Olmesartan Vir, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It lowers elevated blood pressure in adults diagnosed with hypertension. GNH USA supplies Olmesartan Vir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Vir is an antihypertensive agent that acts on the renin‑angiotensin system to control high blood pressure.

Hypertension: reduces systolic and diastolic blood pressure in adults with essential hypertension.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or tiredness - Upper respiratory tract infection symptoms - Diarrhoea or abdominal discomfort - Back pain

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Hyperkalaemia (elevated blood potassium) - Acute kidney injury or worsening renal function - Severe hypotension - Hepatic enzyme elevations - Myocardial infarction (rare)

Olmesartan Vir should be used with caution in specific clinical situations. - Pregnancy: Category D – avoid use during pregnancy due to fetal risk. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution; monitor liver enzymes. - Concomitant potassium‑sparing agents or supplements: watch for hyperkalaemia. - Dual blockade with ACE inhibitors or other ARBs: increase risk of renal dysfunction and hyperkalaemia. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan Vir may interact with several medicines.

Major Interactions (Avoid): - Aliskiren in patients with diabetes: increased risk of renal impairment. - Potassium supplements or potassium‑sparing diuretics: risk of hyperkalaemia. - ACE inhibitors or other ARBs: additive effect on potassium and renal function. - Lithium: may increase lithium serum concentrations. - High dose NSAIDs: can reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive effect, monitor blood pressure. - CYP450 inhibitors (e.g., ketoconazole): may modestly increase olmesartan levels. - Other antihypertensives (beta‑blockers, calcium channel blockers): additive blood pressure lowering, watch for hypotension. - Diuretics that cause volume depletion: monitor renal function and electrolytes. - Antidiabetic drugs: blood pressure reduction may affect glucose control.